- Home
- MOLN vs NRO Comparison
MOLN vs NRO Comparison
Compare MOLN & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- NRO
- Stock Information
- Founded
- MOLN 2004
- NRO 2003
- Country
- MOLN Switzerland
- NRO United States
- Employees
- MOLN N/A
- NRO N/A
- Industry
- MOLN
- NRO Finance/Investors Services
- Sector
- MOLN
- NRO Finance
- Exchange
- MOLN Nasdaq
- NRO Nasdaq
- Market Cap
- MOLN 138.6M
- NRO 156.7M
- IPO Year
- MOLN 2021
- NRO N/A
- Fundamental
- Price
- MOLN $3.57
- NRO $3.23
- Analyst Decision
- MOLN
- NRO
- Analyst Count
- MOLN 0
- NRO 0
- Target Price
- MOLN N/A
- NRO N/A
- AVG Volume (30 Days)
- MOLN 1.8K
- NRO 239.4K
- Earning Date
- MOLN 08-25-2025
- NRO 01-01-0001
- Dividend Yield
- MOLN N/A
- NRO 11.41%
- EPS Growth
- MOLN N/A
- NRO N/A
- EPS
- MOLN N/A
- NRO N/A
- Revenue
- MOLN $2,525,030.00
- NRO N/A
- Revenue This Year
- MOLN N/A
- NRO N/A
- Revenue Next Year
- MOLN $866.67
- NRO N/A
- P/E Ratio
- MOLN N/A
- NRO N/A
- Revenue Growth
- MOLN N/A
- NRO N/A
- 52 Week Low
- MOLN $3.36
- NRO $2.51
- 52 Week High
- MOLN $12.22
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- MOLN 46.42
- NRO 52.98
- Support Level
- MOLN $3.51
- NRO $3.22
- Resistance Level
- MOLN $3.60
- NRO $3.27
- Average True Range (ATR)
- MOLN 0.08
- NRO 0.04
- MACD
- MOLN -0.01
- NRO 0.00
- Stochastic Oscillator
- MOLN 28.95
- NRO 75.00
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").